Amazon.com (NASDAQ:AMZN) stock, currently priced at $1,512.29 per share, has gained 29.4% in 2018 through Monday, Nov. 19. That’s a darn good showing from the e-commerce and cloud-computing giant considering the S&P 500 and Nasdaq indices have returned 2.4% and 1.8%, respectively, over this period.
Although cryptocurrencies have had a miserable year, the technology underlying them, known as blockchain, may have staying power. In particular, blockchain technology offers the ability to transmit money in a secure manner without the need for traditional banking networks. It also allows for the transparent and immutable storage of data. In plain English, it could allow for quicker money transfers and provide use outside the banking industry with regard to data storage. Its utility both within and outside the financial sector is what makes blockchain so intriguing.
The recent stock market sell-off has created opportunities, but it’s also increased risks, especially if you invest in high-flying industries such as biotech that can pop or drop significantly on any day because of clinical trial news. To help you find the best biotech stocks to buy now, we asked three Fool contributors for their best ideas now. There’s no telling what’s in store next for these companies, but they think Global Blood Therapeutics (NASDAQ:GBT), Supernus Pharmaceuticals (NASDAQ:SUPN), and bluebird bio (NASDAQ:BLUE) are top stocks that biotech investors ought to be adding to portfolios this month.
October had more tricks than treats for investors. The markets started clawing their way back during the final two days of the month, but some stocks have still dug themselves into pretty big holes. Many will stay there, but let’s size up the ones that should not.
Imagine that in the next few decades, vehicles will slowly evolve from machines that we are entirely in control of to ones that become artificially intelligent chauffeurs, tirelessly carting us around town day and night.
Want a high-growth stock but don’t want to deal with the exceptional volatility and concerns about business longevity that come with owning small-cap stocks? Then say hello to mid-cap stocks, which can offer the perfect blend of growth, value, and more established business models.
A 3.5% dividend yield and a long track record of dividend increases have turned PepsiCo Inc.(NASDAQ:PEP) into a core holding for many income investors, but Pepsi isn’t the only big company that’s paying a market-beating dividend. In fact, other companies may offer investors a better blend of potential price appreciation and dividends than it does. To help you find those stocks, we asked three Motley Fool contributors to offer up companies they like more than Pepsi. Read on to find out why they think Pepsi lovers ought to consider TerraForm Power(NASDAQ:TERP), AstraZeneca. (NYSE:AZN), and Royal Dutch Shell (NYSE:RDS-A)(NYSE:RDS-B) instead.
Marijuana stocks have been on fire lately, with investors looking at the rising tide of new jurisdictions in which marijuana is becoming legal for recreational use. With the entire nation of Canada legalizing recreational cannabis later this month, the companies that will provide the marijuana that users want to smoke see a potential gold mine ahead.
Is your goal to get rich? There’s lots of advice out there about how to do it, and a lot of it centers on spending less so you can save more.
Canada’s Tilray (NASDAQ:TLRY), a marijuana cultivator and distributor, has given early investors the ride of their lives since going public last June. Last week, for instance, the company’s stock peaked at exactly $300 per share, representing a jaw-dropping 856% gain for the brave souls that bought this speculative IPO right off the bat.